RP-3 is under clinical development by Replimune and currently in Phase I for Lung Cancer.
Affluent Medical announces positive clinical results and further insights to enhance its strategy on Structural Heart activities – Biotech Investments
EQS-News: Affluent Medical SA / Key word(s): Study results Affluent Medical announces positive clinical results and further insights to enhance its strategy on Structural Heart